Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 13_Supplement; p. CT212
• Main Authors: Janku, Filip, Sherman, Eric, Yaeger, Rona, Parikh, Aparna, Sullivan, Ryan, Feun, Lynn, Fuente, Macarena De La, Tsai, Frank Yung-Chin, Gordon, Michael, Allen, Carl, Rudoltz, Marc S., Balinski, Kathe, Averbuch, Steven, Vidne, Michael, Tarcic, Gabi
• Format: Journal Article
• Language: English
• Published: 01-07-2021
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2021-CT212

Abstract
The authors did not submit an updated abstract. The original abstract should be considered final.
Citation Format: Filip Janku, Eric Sherman, Rona Yaeger, Aparna Parikh, Ryan Sullivan, Lynn Feun, Macarena De La Fuente, Frank Yung-Chin Tsai, Michael Gordon, Carl Allen, Marc S. Rudoltz, Kathe Balinski, Steven Averbuch, Michael Vidne, Gabi Tarcic. Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT212.